Sharma and colleagues used the non-small-cell lung carcinoma (NSCLC) cell line PC9 to show that treatment with receptor tyrosine kinase-inhibitors (RTKi) results in incomplete depletion of tumour cells, as a small subpopulation was not affected by the treatment [70]. The gene discussed is NTRK1; the disease is non-small cell lung carcinoma.